Nov 4, 2025
At Precision AQ, we know that navigating patient access challenges requires more than data—it takes real-world expertise. That’s why we’ve launched our Meet Our Access Experience Team series, introducing the industry insiders who help life science companies anticipate payer challenges, optimize access strategies, and accelerate time to therapy.
Meet Molly Borchardt, PharmD, director of the Access Experience team at Precision AQ. Let’s hear from Molly.
Q&A with Molly Borchardt
Q: Can you share a bit about your background and areas of specialty?
I’m a pharmacist by training, having earned my PharmD from the University of Minnesota. Before joining Precision AQ two years ago, I spent over a decade in the specialty and managed care space. My career began at a home infusion company, where I led their Hemophilia Center of Excellence. That experience sparked a deep interest in rare diseases and specialty drug management, which I carried forward into roles at Prime Therapeutics and Blue Cross Blue Shield of North Carolina.
I’m particularly passionate about access to rare disease therapies and the evolving landscape of cell and gene treatments. I also enjoy collaborating with actuarial and finance teams to explore the intersection of clinical innovation and affordability.
Q: Where did you work prior to Precision AQ?
- Blue Cross Blue Shield of North Carolina – Director of Specialty
- Prime Therapeutics – Specialty Clinical Program Director
- Coram CVS Specialty Infusion Services – Supervisor, Hemophilia Center of Excellence
Q: What unique perspectives do you bring to ensuring patient access?
Starting my career in direct patient care gave me a firsthand understanding of the challenges patients and caregivers face, especially in the rare disease space. That experience informs my approach to access strategy, helping me advocate for solutions that balance clinical value with affordability. I believe population-based decision makers have a responsibility to support innovation while ensuring sustainable access to current and future therapies.
Q: Which healthcare trends aren’t getting enough attention?
There’s a growing wave of innovation among smaller vendors that are disrupting traditional models. These organizations are often overlooked, yet they’re playing a critical role in reshaping how care is delivered and accessed.
Q: Which trends will reshape healthcare in the next 1–3 years?
- Longer-term, potentially curative therapies – While this shift has been underway for some time, questions remain around how to finance these treatments sustainably.
- Drug pricing regulations – From the Inflation Reduction Act (IRA) to Most Favored Nation (MFN) policies and state-level Prescription Drug Affordability Boards (PDABs), we’re seeing a significant transformation in how pricing decisions are made. These changes could have far-reaching implications, and the entire healthcare ecosystem must be taken into account in policy development.
Q: What are you most passionate about in healthcare?
Innovation and transparency. I’m driven by the potential of new therapies to transform lives, and I believe transparency is key to building trust across stakeholders.
Q: What do you enjoy most about working at Precision AQ?
The Access Experience Team is an incredible group of professionals. I love the collaborative environment and the depth of expertise we share. In previous roles, I often worked independently or on smaller teams, so having access to such a broad and knowledgeable network has been a game-changer.
Q: What should life science organizations prioritize in innovation?
It’s essential to engage access decision makers early and consistently throughout the development process. Their insights, alongside those of other stakeholders, can help shape strategies that are both clinically meaningful and economically viable.
About Precision AQ’s Access Experience Team
Precision AQ’s Access Experience Team (AET), originally launched in 2009, was created to bridge the gap between payers and life sciences companies, offering deep insight into access decision-making. Comprising more than 25 former access decision-makers from prominent managed care organizations, specialty pharmacies, and health plans, the AET brings firsthand experience to payer strategies, reimbursement barriers, and evolving policies. As an integrated part of Precision AQ, the AET helps clients translate payer practices and market access insights into actionable strategies to improve patient access.
Want to connect? Reach out to molly.borchardt@precisionaq.com.